1. An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells
- Author
-
Alexandre Nicolas, Gérémy Sannier, Mathieu Dubé, Manon Nayrac, Alexandra Tauzin, Mark M. Painter, Rishi R. Goel, Mélanie Laporte, Gabrielle Gendron-Lepage, Halima Medjahed, Justine C. Williams, Nathalie Brassard, Julia Niessl, Laurie Gokool, Chantal Morrisseau, Pascale Arlotto, Cécile Tremblay, Valérie Martel-Laferrière, Andrés Finzi, Allison R. Greenplate, E. John Wherry, and Daniel E. Kaufmann
- Subjects
Biological sciences ,Immunology ,Components of the immune system ,Science - Abstract
Summary: Spacing the first two doses of SARS-CoV-2 mRNA vaccines beyond 3–4 weeks raised initial concerns about vaccine efficacy. While studies have since shown that long-interval regimens induce robust antibody responses, their impact on B and T cell immunity is poorly known. Here, we compare SARS-CoV-2 naive donors B and T cell responses to two mRNA vaccine doses administered 3–4 versus 16 weeks apart. After boost, the longer interval results in a higher magnitude and a more mature phenotype of RBD-specific B cells. While the two geographically distinct cohorts present quantitative and qualitative differences in T cell responses at baseline and after priming, the second dose led to convergent features with overall similar magnitude, phenotype, and function of CD4+ and CD8+ T cell responses at post-boost memory time points. Therefore, compared to standard regimens, a 16-week interval has a favorable impact on the B cell compartment but minimally affects T cell immunity.
- Published
- 2023
- Full Text
- View/download PDF